Copyright
©2014 Baishideng Publishing Group Inc.
World J Clin Oncol. Dec 10, 2014; 5(5): 1078-1087
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1078
Published online Dec 10, 2014. doi: 10.5306/wjco.v5.i5.1078
Figure 2 HLA-DR, CD163 and CD36 expression on (CD14+/CD16-) blood classical monocytes in patients with primary non-small cell lung cancer compared to controls.
Summary graphs show the mean values of MFI ± SEM of (A) HLA-DR, (B) CD163 and (C) CD36 markers from patients with non-small cell lung cancer (NSCLC) vs non-cancer controls.
- Citation: Almatroodi SA, McDonald CF, Collins AL, Darby IA, Pouniotis DS. Blood classical monocytes phenotype is not altered in primary non-small cell lung cancer. World J Clin Oncol 2014; 5(5): 1078-1087
- URL: https://www.wjgnet.com/2218-4333/full/v5/i5/1078.htm
- DOI: https://dx.doi.org/10.5306/wjco.v5.i5.1078